Table 4.
Candidate LMP-2 epitopes identified by ex vivo screening of PBMC or identified in association with HLA alleles relevant to this study [13]
| Candidate epitope | Donor | Candidate HLA-allele | [13] | HLA in [13] |
|---|---|---|---|---|
| Matrix A | ||||
| *LMP-2: - 2 pylfwlaai* | – | – | + | A23/24 |
| LMP-2:4 laaiaascf | 2, 8, 16, (17) | A2, B57, DR07 | – | – |
| LMP-2:6 aiaascfta | 8, 10, 16, 27, (17) | A2, A24, DR07 | - | - |
| LMP-2:10 scftasvst | 2, 27 | B 57/58 | - | - |
| LMP-2:15 svstvvtat | 2, 7, 8 | A1, A11, C6 | – | – |
| LMP-2:25 lalslllla | 8 | A2, B57 | – | – |
| LMP-2:50 vtvltavvt | 2, 9, 26 | A2, B35, C4 | – | – |
| LMP-2:75 sllfallaa | 2, 8 | A 2, B57, C6 | – | – |
| LMP-2:84 agglqgiyvl | (17) | DR07 | – | – |
| LMP-2:94 vmlvllila | 2 | A2 | – | – |
| *LMP-2:104 rrrwrrltv* | 8a, 12, 24 | B27 | + | B27 |
| LMP-2:107 wrrltvcgg | 8a, 12, 24 | B27 | – | – |
| *LMP-2:108 rrltvcggi* | – | – | + | B27 |
| *LMP-2:111 tvcggimfl* | – | – | + | A0101/06 |
| LMP-2:115 gimflacvl | 8 | A2, B27 | – | – |
| Matrix B | ||||
| LMP-2:123 lvlivdavl | 2, 8 | A*0201 | – | – |
| *LMP-2:125 livdavlql* | – | – | + | A0204 or 0217 |
| LMP-2:136 llgavtvvs | 2, 8 | A*0201 | – | – |
| LMP-2: 145 mtllllafv | 1, 2 | A*0205, B57/58 | – | – |
| LMP-2: 155 wlsspgglg | 1, 2, 8, | A*0205/0201 | - | - |
| *LMP-2:161 glgtlgaal* | – | – | + | A2 |
| *LMP-2:197 llwtlvvl* | – | – | + | A*0101 |
| LMP-2:203–206 vllicsscsscp | 2, 3, 8 | A2, B57, C6 | – | – |
| *LMP-2:208 sscsscpls* | – | – | + | A11 |
| *LMP-2:213 cplskilla* | 2, 8, 27 | B 57/58, C 6/7 | - | |
| *LMP-2:224 flyalalll* | - § | A*0201 | + | A0201 |
| Matrix C | ||||
| *LMP-2:287 tygpvfmcl* | 5, 23, 9 | A24 | + | A24 |
| *LMP-2:294–297 clgglltmvaga* | 2, 5, 6 c, 10, 13, 16(?) | A*0201/03/07 | + | A0201/06/07 |
| LMP-2:304–307 gavwltvmtntl | 1, 2, 4, 5 d, 6, 13 | A*0201/03/05/07 | – | – |
| LMP-2:319 wiltagfli | 8, 10, 24, 26 | A*0201 | – | – |
| *LMP-2:321 ltagflifl* | –§ | A2 | + | A2 |
Underlined epitopes that have been confirmed by intra-cellular cytokine staining (ICS)—when overlapping epitopes were identified only the amino acid sequence that yielded the highest frequency of epitope-specific cells by ICS is underlined
The donors in which reactivity was identified are shown and specific reactivity was based on a cut-off (n)log2 IFNγ/β-actin = 1.04 for Caucasian donors and 1.028 for Chinese donors as described in the Materials and methods
*Epitopes already known
§Epitopes identified by ICF only
(17) This donor CD4+ T cells responded to epitope stimulation as detected by ICS
aSee Fig. 3 (pept 104)
bSee Fig. 2 (pept 294)